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background: Long-term outcomes following TAVI are still limited. Valve durability is vital to expansion of TAVI to younger patients and those at 
lower-risk of surgical mortality. We evaluated the long-term effectiveness of the Medtronic CoreValve System (18F) to 4 years from the multicenter, 
controlled, single-arm CoreValve CE Pivotal Study.
Methods: The Study prospectively enrolled 126 patients at 9 sites in Europe and Canada 08 May, 2006 to 19 November, 2008. Patients were 
included if they had severe symptomatic AS and were at high risk for SAVR. Procedures included 100% monitoring and use of an independent Echo 
Core Lab and Clinical Events Committee. Valve performance, QOL (EQ5D), and survival thru 4-year follow-up were analyzed.
results: Baseline mean age was 82 years, 43% male, EuroSCORE 23.4%, CAD 65.9%, chronic lung disease 23.0%, prior CABG 26.2%, prior PCI 
23.8%, peripheral vascular disease 19.0%, and porcelain aorta 7.9%. QOL and valve parameters are in Table. At 4 years, 74% of surviving patients 
with paired data had improved NYHA vs. baseline. No valve migration or structural valve dysfunction were identified during the study. The rate of 
cardiac death was 17.7% at 1 year, and 37.4% at 4 years.
conclusions: The CoreValve Pivotal CE Study is the first controlled, prospective study to use an Echo Core Lab for serial long-term valve 
assessment. At 4 years there were no changes in performance of the CoreValve bioprosthesis and most surviving patients continued to have 
improved QOL.
QOL and Valve Parameters Through 4 Years
Baseline Discharge 1 Year 2 Years 3 Years 4 Years
Mean AV Gradient, mm Hg, mean (SD)* 46.9 (16.1) 9.8 (4.1) 10.3 (3.8) 9.0 (3.2) 8.7 (2.9) 7.8 (2.7)
Effective Orifice Area,cm3, mean (SD)* 0.7 (0.2) 1.8 (0.4) 1.7 (0.3) 1.7 (0.3) 1.6 (0.3) 1.6 (0.5)
LV Ejection Fraction, %, mean (SD)* 51.6 (13.1) 55.7 (12.1) 56.2 (10.5) 53.6 (12.4) 48.0 (10.5) 52.8 (10.1)
NYHA Class I/II, % 25.0 84.2† 88.0† 81.9† 80.0† 89.4†
NYHA Class III,IV % 75.0 15.8† 12.0† 18.1† 20.0† 10.6†
EQ5D-No Problem Performing Usual Activities, % 37.1 NM 53.3 56.9 61.5 61.8
*For patients with available echo data.
†In patients alive.
NM=Not measured.
